AstraZeneca PLC (NASDAQ:AZN), a pharmaceutical and biotech firm based in Cambridge, UK, reported positive results from its Phase 3b Batura trial. The study found that Airsupra, its dual-action asthma rescue inhaler, led to meaningful improvements in patients with mild asthma compared to albuterol alone.AstraZeneca PLC (AZN) Trial: Airsupra Cuts Severe Asthma Risk by 47%

AIRSUPRA is the only FDA-approved rescue inhaler designed to both relieve asthma symptoms and help prevent asthma attacks. It is a pressurized metered-dose inhaler that combines albuterol and budesonide. The FDA approved the inhaler in January 2023 for use as needed to manage or prevent asthma symptoms and reduce the risk of sudden, severe breathing issues in adults aged 18 and older.

In a recent trial, the results showed that Airsupra reduced the risk of severe asthma flare-ups by 47% versus placebo. In addition, patients using the inhaler had 63% less exposure to systemic corticosteroids during treatment, lowering the risk of long-term side effects such as type 2 diabetes, mental health issues, kidney problems, cataracts, heart disease, pneumonia, and bone fractures.

Sharon Barr, Executive Vice-President and Head of BioPharmaceuticals R&D, AstraZeneca PLC (NASDAQ:AZN), made the following statement:

“The exciting results from the BATURA trial, coupled with the findings from MANDALA and DENALI, clearly demonstrate the superiority of Airsupra over albuterol alone across all asthma severities. We hope these comprehensive results accelerate the use of anti-inflammatory rescue therapy as the preferred standard of care, in line with recommendations from the Global Initiative for Asthma.”

Airsupra made a favorable contribution to AstraZeneca PLC (NASDAQ:AZN)'s earnings and has the potential to play a more significant role in future profits, particularly in light of the recent trial results. In fiscal year 2024, Airsupra brought in $66 million in revenue.

While we acknowledge the potential of AZN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than AZN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Mid-Cap Dividend Aristocrats to Invest in Now and Dividend Challengers 2025: Top 25

Disclosure. None.

View Comments